J. Rosenberg

5.3k total citations · 3 hit papers
29 papers, 4.2k citations indexed

About

J. Rosenberg is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, J. Rosenberg has authored 29 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pathology and Forensic Medicine, 10 papers in Genetics and 9 papers in Oncology. Recurrent topics in J. Rosenberg's work include Lymphoma Diagnosis and Treatment (13 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). J. Rosenberg is often cited by papers focused on Lymphoma Diagnosis and Treatment (13 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). J. Rosenberg collaborates with scholars based in United States, Canada and Finland. J. Rosenberg's co-authors include A.J. Grillo-López, Ronald Levy, DG Maloney, Christine A. White, Antonio J Grillo-López, David G. Maloney, Peter McLaughlin, C. Varns, Brian K. Link and Ivor Royston and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Neurology.

In The Last Decade

J. Rosenberg

29 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma

1994 604 citations DG Maloney, J. Rosenberg et al. Blood profile →
IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.

1997 527 citations DG Maloney, A.J. Grillo-López et al. Journal of Clinical Oncology profile →
Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-Treatment

2000 523 citations Antonio J Grillo-López, Christine A. White et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J. Rosenberg United States	17	2.2k	1.8k	1.2k	1.2k	1.0k	29	4.2k
Arne Kolstad Norway	28	2.1k 1.0×	908 0.5×	718 0.6×	1.9k 1.6×	720 0.7×	121	3.5k
Simonetta Viviani Italy	33	3.2k 1.5×	755 0.4×	471 0.4×	1.9k 1.6×	419 0.4×	119	4.4k
A. Z. S. Rohatiner United Kingdom	43	4.2k 1.9×	2.1k 1.2×	1.1k 0.9×	3.1k 2.6×	945 0.9×	117	6.8k
Sunil Agarwal United States	10	1.8k 0.8×	460 0.3×	357 0.3×	471 0.4×	1.3k 1.3×	19	3.1k
Adam J. Olszewski United States	28	1.3k 0.6×	781 0.4×	151 0.1×	1.3k 1.1×	363 0.3×	212	3.1k
Michael Møller Denmark	34	1.6k 0.7×	1.0k 0.6×	95 0.1×	1.3k 1.1×	945 0.9×	161	4.2k
Agnieszka Korfel Germany	35	2.5k 1.2×	2.2k 1.2×	199 0.2×	715 0.6×	135 0.1×	128	3.7k
Lucienne Michaux Belgium	38	1.4k 0.6×	1.3k 0.7×	187 0.2×	1.1k 0.9×	982 0.9×	184	4.5k
Lorenza Gandola Italy	37	1.2k 0.5×	1.3k 0.7×	179 0.1×	1.6k 1.4×	304 0.3×	148	5.2k
Uri Tabori Canada	44	744 0.3×	3.2k 1.8×	341 0.3×	1.1k 0.9×	260 0.2×	219	6.7k

Countries citing papers authored by J. Rosenberg

Since Specialization

Citations

This map shows the geographic impact of J. Rosenberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Rosenberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Rosenberg more than expected).

Fields of papers citing papers by J. Rosenberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Rosenberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Rosenberg. The network helps show where J. Rosenberg may publish in the future.

Co-authorship network of co-authors of J. Rosenberg

This figure shows the co-authorship network connecting the top 25 collaborators of J. Rosenberg. A scholar is included among the top collaborators of J. Rosenberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Rosenberg. J. Rosenberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Retz, Margitta, José Luis Perez‐Gracia, Andrea Necchi, et al.. (2016). 1142 Efficacy of atezolizumab (MPDL3280A) in platinum-treated metastatic urothelial carcinoma (mUC): Update from the IMvigor 210 phase II clinical trial. European Urology Supplements. 15(3). e1142–e1142a. 1 indexed citations

Rosenberg, J., Daniel P. Petrylak, Oyewale O. Abidoye, et al.. (2015). 21LBA Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): Results from a pivotal multicenter phase II study (IMvigor 210). European Journal of Cancer. 51. S720–S720. 10 indexed citations

Jordan, Emmet, Antoun Toubaji, Aditya Bagrodia, et al.. (2015). 2650 Assessment of genomic alterations in bladder adenocarcinoma and urachal adenocarcinoma. European Journal of Cancer. 51. S530–S530. 5 indexed citations

Kim, Hyuncheol, Karl G. Csaky, Chi‐Chao Chan, et al.. (2005). The pharmacokinetics of rituximab following an intravitreal injection. Experimental Eye Research. 82(5). 760–766. 70 indexed citations

Davis, John C., et al.. (2001). Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus.. PubMed. 28(1). 95–101. 121 indexed citations

Czuczman, M. S., A.J. Grillo-López, Peter McLaughlin, et al.. (2001). Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy. Annals of Oncology. 12(1). 109–114. 54 indexed citations

Byrd, John C., Timothy J. Murphy, Robin Howard, et al.. (2001). Rituximab Using A Thrice Weekly Dosing Schedule in B-Cell Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Demonstrates Clinical Activity and Acceptable Toxicity. Journal of Clinical Oncology. 19(8). 2153–2164. 411 indexed citations

Wiklund, Tom, Juhani Collan, Rita Janes, et al.. (2001). Complement Activation in Circulation and Central Nervous System after Rituximab (Anti-CD20) Treatment of B-Cell Lymphoma. Leukemia & lymphoma. 42(4). 731–738. 74 indexed citations

Grillo-López, A.J., B.K. Dallaire, C. Varns, et al.. (2000). Rituximab The First Monoclonal Antibody Approved for the Treatment of Lymphoma. Current Pharmaceutical Biotechnology. 1(1). 1–9. 118 indexed citations

10.

Silberstein, Stephen D. & J. Rosenberg. (2000). Multispecialty consensus on diagnosis and treatment of headache. Neurology. 54(8). 1553–1553. 109 indexed citations

11.

Byrd, John C., Christine A. White, Brian K. Link, et al.. (1999). Rituximab therapy in Waldenstrom's macroglobulinemia: Preliminary evidence of clinical activity. Annals of Oncology. 10(12). 1525–1527. 85 indexed citations

12.

Miller, Robert G., J. Rosenberg, Deborah Gelinas, et al.. (1999). Practice parameter: The care of the patient with amyotrophic lateral sclerosis (an evidence-based review) [RETIRED]. Neurology. 52(7). 1311–1311. 411 indexed citations

13.

Miller, Robert G., J. Rosenberg, Deborah Gelinas, et al.. (1999). Practice parameter: The care of the patient with amyotrophic lateral sclerosis (An evidence-based review). Muscle & Nerve. 22(8). 1104–1118. 121 indexed citations

14.

Chinn, Paul, John E. Leonard, J. Rosenberg, Nabil Hanna, & David R. Anderson. (1999). Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma.. International Journal of Oncology. 15(5). 1017–25. 71 indexed citations

15.

Berinstein, Neil L., A.J. Grillo-López, Christine A. White, et al.. (1998). Association of serum Rituximab (IDEC–C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma. Annals of Oncology. 9(9). 995–1001. 444 indexed citations

16.

Maloney, DG, A.J. Grillo-López, David Bodkin, et al.. (1997). IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.. Journal of Clinical Oncology. 15(10). 3266–3274. 527 indexed citations breakdown →

17.

Bodkin, David, et al.. (1995). Pharmacokinetic analysis of serum concentrations of the chimeric anti-CD20 antibody IDEC-C2B8 in patients with relapsed B cell lymphoma. 36. 365. 3 indexed citations

18.

Maloney, DG, et al.. (1994). Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 84(8). 2457–2466. 604 indexed citations breakdown →

19.

Grillo-López, A.J., DG Maloney, David Bodkin, et al.. (1994). IDEC-C2B8. Journal of Immunotherapy. 16(3). 236–236. 1 indexed citations

20.

Rosenberg, J.. (1988). Constitutional Rights and Civil Forfeiture Actions. Columbia Law Review. 88(2). 390–390. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact